
Core Insights - Beyond Air, Inc. is set to report its financial results for the first fiscal quarter ending June 30, 2025, on August 12, 2025, with a conference call scheduled for 4:30 PM ET [1] - The company focuses on utilizing nitric oxide to enhance the treatment of patients with respiratory illnesses, neurological disorders, and solid tumors [3][4] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company that has received FDA approval and CE Mark for its LungFit® PH system, aimed at treating hypoxic respiratory failure in neonates [3] - The company is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [3] - Beyond Air has partnered with The Hebrew University of Jerusalem to develop a pre-clinical program for autism spectrum disorder and other neurological disorders [4] - An affiliate, Beyond Cancer, is investigating ultra-high concentrations of nitric oxide for targeting solid tumors in pre-clinical settings [4]